Monoclonal Antibody chP3R99 Reduces Subendothelial Retention of Atherogenic Lipoproteins in Insulin-Resistant Rats: Acute Treatment Versus Long-Term Protection as an Idiotypic Vaccine for Atherosclerosis.
Yosdel SotoArletty HernándezRoger SarduyVictor BritoSylvie MarleauDonna F VineAna M VázquezSpencer D ProctorPublished in: Journal of the American Heart Association (2024)
Both acute (passive) and long-term administration (idiotypic cascade) of chP3R99 antibody reduced low-density lipoprotein and remnant lipoprotein interaction with proteoglycans in an insulin-resistant setting. These findings support the innovative approach of targeting proatherogenic lipoprotein retention by chP3R99 as a passive therapy or as an idiotypic vaccine for atherosclerosis.
Keyphrases
- low density lipoprotein
- monoclonal antibody
- liver failure
- type diabetes
- respiratory failure
- cardiovascular disease
- drug induced
- aortic dissection
- glycemic control
- cancer therapy
- hepatitis b virus
- stem cells
- drug delivery
- adipose tissue
- cell therapy
- insulin resistance
- extracorporeal membrane oxygenation
- replacement therapy